文献速递神经MR

治疗后胶质瘤中钆布醇与钆特酸葡甲胺动态对比增强参数的比较:一项前瞻性个体内研究

Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-10-15

前瞻性纳入32例治疗后胶质瘤患者,每例分别接受钆布醇与钆特酸葡甲胺两次20分钟动态对比增强检查,比较无模型参数及Tofts模型药代动力学参数。两种对比剂在信号强度曲线下面积及Ktrans、Ve、Vp、Kep上均无显著差异(均P>.05);钆布醇洗入率更高、洗出率更低,支持两者在动态对比增强成像中可互换使用。

要点

  • 钆布醇与钆特酸葡甲胺的动态对比增强药代动力学参数(Ktrans、Ve、Vp、Kep)无显著差异。
  • 钆布醇平均洗入率高于钆特酸葡甲胺,平均洗出率低于钆特酸葡甲胺。
  • 进展组较治疗相关改变组呈现曲线下面积、Ktrans、Ve、Vp、洗入及洗出率偏高、Kep偏低的趋势,与所用对比剂无关。

核心结论

  • 两种钆对比剂的无模型参数和药代动力学参数无显著差异,仅钆布醇洗入率更高、钆特酸葡甲胺洗出率更高,支持在治疗后胶质瘤动态对比增强成像中互换使用。

研究设计与样本

  • 前瞻性个体内研究,纳入32例治疗后胶质瘤患者,每例接受2次20分钟动态对比增强检查,分别使用一摩尔非离子型钆布醇与半摩尔离子型钆特酸葡甲胺,采用配对t检验进行个体内比较;患者进一步分为进展组(n=12)与稳定组(n=20),采用Student t检验比较。

诊断标准与关键数值

  • 计算并比较30至1100秒信号强度曲线下面积(无模型参数)及Tofts模型药代动力学参数;两种对比剂在曲线下面积及Ktrans、Ve、Vp、Kep上均无显著差异(均P>.05);钆布醇平均洗入率0.83±0.64 vs 钆特酸葡甲胺0.29±0.63(P=.013),钆布醇平均洗出率0.001±0.0001 vs 钆特酸葡甲胺0.002±0.002(P=.02)。

临床应用与阅片要点

  • 作者认为,除洗入率与洗出率外两种对比剂参数无显著差异,支持在治疗后胶质瘤动态对比增强成像中互换使用钆布醇与钆特酸葡甲胺。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Differences in molecular properties between one-molar and half-molar gadolinium-based contrast agents are thought to affect parameters obtained from dynamic contrast-enhanced imaging. The aim of our study was to investigate differences in dynamic contrast-enhanced parameters between one-molar nonionic gadobutrol and half-molar ionic gadoterate meglumine in patients with posttreatment glioma.

MATERIALS AND METHODS: This prospective study enrolled 32 patients who underwent 2 20-minute dynamic contrast-enhanced examinations, one with gadobutrol and one with gadoterate meglumine. The model-free parameter of area under the signal intensity curve from 30 to 1100 seconds and the Tofts model-based pharmacokinetic parameters were calculated and compared intraindividually using paired t tests. Patients were further divided into progression (n = 12) and stable (n = 20) groups, which were compared using Student t tests.

RESULTS: Gadobutrol and gadoterate meglumine did not show any significant differences in the area under the signal intensity curve or pharmacokinetic parameters of K trans, Ve, Vp, or Kep (all P > .05). Gadobutrol showed a significantly higher mean wash-in rate (0.83 ± 0.64 versus 0.29 ± 0.63, P = .013) and a significantly lower mean washout rate (0.001 ± 0.0001 versus 0.002 ± 0.002, P = .02) than gadoterate meglumine. Trends toward higher area under the curve, K trans, Ve, Vp, wash-in, and washout rates and lower Kep were observed in the progression group in comparison with the treatment-related-change group, regardless of the contrast agent used.

CONCLUSIONS: Model-free and pharmacokinetic parameters did not show any significant differences between the 2 gadolinium-based contrast agents, except for a higher wash-in rate with gadobutrol and a higher washout rate with gadoterate meglumine, supporting the interchangeable use of gadolinium-based contrast agents for dynamic contrast-enhanced imaging in patients with posttreatment glioma.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Park JE, Kim JY, Kim HS, et al. Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study. AJNR Am J Neuroradiol. 2020. PMID: 33060100. doi:10.3174/ajnr.A6792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。